Insider Selling: Equillium (NASDAQ:EQ) COO Sells 86,012 Shares of Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 86,012 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $2.80, for a total value of $240,833.60. Following the transaction, the chief operating officer directly owned 62,586 shares of the company’s stock, valued at approximately $175,240.80. The trade was a 57.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The shares were sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Stock Up 2.1%

NASDAQ EQ traded up $0.06 on Friday, reaching $2.90. 853,917 shares of the stock traded hands, compared to its average volume of 480,896. The firm’s fifty day simple moving average is $2.09 and its 200 day simple moving average is $1.63. The company has a market cap of $183.37 million, a price-to-earnings ratio of -9.06 and a beta of 1.67. Equillium, Inc. has a 12 month low of $0.27 and a 12 month high of $3.10.

Equillium (NASDAQ:EQ) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). As a group, equities research analysts forecast that Equillium, Inc. will post -0.24 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on EQ shares. B. Riley Financial initiated coverage on Equillium in a research report on Thursday, April 16th. They set a “buy” rating and a $6.00 target price on the stock. Oppenheimer initiated coverage on Equillium in a research note on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a report on Friday, March 27th. Zacks Research raised shares of Equillium to a “hold” rating in a research note on Thursday, February 26th. Finally, Leerink Partners upgraded shares of Equillium from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $1.00 to $6.00 in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.57.

Institutional Trading of Equillium

Hedge funds have recently modified their holdings of the business. Aberdeen Group plc purchased a new stake in shares of Equillium in the third quarter valued at $543,000. Vanguard Group Inc. lifted its holdings in shares of Equillium by 59.4% in the third quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company’s stock valued at $1,879,000 after purchasing an additional 489,855 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Equillium in the third quarter valued at $99,000. Two Sigma Investments LP purchased a new stake in shares of Equillium in the third quarter valued at $190,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Equillium in the third quarter valued at $7,951,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Key Stories Impacting Equillium

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.